drugset / Trial / NCT01895257

Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer

NCT01895257 ↗

Phase 3 Unknown 162 enrolled University of Antwerp
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigators propose to conduct a randomised phase III trial evaluating a maintenance strategy comparing hepatic arterial injection of Yttrium-90 resin microspheres plus continuing simplified chemotherapy with/without targeted therapy versus continuing simplified chemotherapy with/without targeted therapy alone for patient with dominant or exclusive and unresectable liver mCRC controlled after 3-6 months of chemotherapy induction.

Timeline

Start
2013-08
Primary completion
2017-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Leucovorin L Unknown 200 mg/m2 Intravenous
Comparator Leucovorin L Unknown 400 mg/m2 Intravenous
Comparator fluorouracil Small molecule 400 mg/m2 Intravenous
Comparator fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications